Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here
Drugs in Development / Clinical Trials—Updated September 17, 2014
Tuesday, September 23, 2014
“He called me in and I went down there and that’s when he told me I had hepatitis C,” Riley explained. “I said ‘Well, how long have I had it?’ He said, ‘I’m assuming from the things you’ve told me, you’ve had it 25 to 30 years.’”
“It just lay dormant and then all of a sudden it blossomed like a rose,” Riley, of Kenosha, said.
NICE's appraisal consultation document (ACD) has recommended the drug for the treatment of chronic hepatitis C genotype 1 infection, but did not recommend it for use in combination with sofosbuvir for patients who are unable to tolerate an interferon-based regimen with genotypes 1 or 4 hepatitus C.
Peter Barnes, medical director at Janssen, said: “We are pleased that simeprevir has been recommended for the treatment of patients with genotype 1 hepatitis C when used in combination with peginterferon and ribavirin.
“However, we are disappointed with the preliminary recommendations from NICE for genotype 4 patients and those who are intolerant to interferon and could therefore benefit from the use of a treatment regime that does not include it.”
Barbara Walter has experienced the full medical odyssey of chronic hepatitis C infection, having faced its every major challenge while benefiting from all of the modern breakthrough treatments.
She is one of the lucky few. She is cured, with no detectable virus in her blood since July.
Monday, September 22, 2014
“Screening for incidence HCV is variable across sites and improvement in frequency of screening is also variable, highlighting the a need for US-based guidelines to inform HIV practice,” write the authors.
An editorial in the same issue of the journal stresses the importance of prompt HCV diagnosis in people living with HIV.
Thirty-one-year-old Mike knows the van, and knows it well – it's where he can find clean works.
For the last seven years that van, the hub for the state's needle exchange program, has traveled to at-risk areas in Wilmington, serving as a clean syringe clearinghouse for those living with a drug addiction.
In Malaysia, it is estimated that as at 2010 the HCV infections were at 397,515. According to a report in The Star dated June 8, 2014, the present rate of infection is likely to be much higher as often many infected with hepatitis C are not aware of their status.
In this context, new oral medicines bring significant new hope for many people infected with the Hepatitis C virus with its better cure rates and lesser side effects. However, hopes for universal affordable curable treatment were dashed with Gilead’s announcement on Sept 15 of a voluntary licence on two direct-acting oral antivirals (DAAs) used to treat HCV infections, sofosbuvir (Sovaldi®) and ledipasvir.